SCOPUS 정보 검색 플랫폼

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 9, 2015, Pages 705-711

QT-prolonging effects of monoclonal antibody drugs in humans: A systematic review of two literature and a public adverse event database

(3) Jackson, Torquil a Kondic, Jelena a Seebeck, Joerg a

a Prime Vigilance Ltd (United Kingdom)

Author keywords

Arrhythmia; Biologics; LQTS; Monoclonal antibody; QT prolongation; Signal

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BELIMUMAB; BESILESOMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DENOSUMAB; ECULIZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; PERTUZUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB; USTEKINUMAB;

ARTICLE; EUROPE; HUMAN; HYPOCALCEMIA; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; DRUG EFFECTS; ELECTROCARDIOGRAPHY; FACTUAL DATABASE;

ANTIBODIES, MONOCLONAL; DATABASES, FACTUAL; ELECTROCARDIOGRAPHY; HUMANS;

EID: 84941131966 PISSN: 09461965 EISSN: None Source Type: Journal
DOI: 10.5414/CP202337 Document Type: Article

Times cited : (7)

References (11)

1
- 77958500384
- Drug-induced arrhythmia
- CrossRef PubMed
- Heist EK, Ruskin JN. Drug-induced arrhythmia. Circulation. 2010; 122: 1426-1435. CrossRef PubMed
- (2010) Circulation , vol.122 , pp. 1426-1435
- Heist, E.K.¹ Ruskin, J.N.²

2
- 84868668351
- Druginduced QT interval prolongation: Mechanisms and clinical management
- CrossRef PubMed
- Nachimuthu S, Assar MD, Schussler JM. Druginduced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012; 3: 241-253. CrossRef PubMed
- (2012) Ther Adv Drug Saf , vol.3 , pp. 241-253
- Nachimuthu, S.¹ Assar, M.D.² Schussler, J.M.³

3
- 33746627036
- Anonymous. FDA October [accessed: October 7, 2014].
- Anonymous. Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic drugs. FDA October 2005; http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm073153.pdf [accessed: October 7, 2014].
- (2005) Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs

4
- 78650122732
- Drug-induced long QT syndrome
- CrossRef PubMed
- Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010; 62: 760-781. CrossRef PubMed
- (2010) Pharmacol Rev , vol.62 , pp. 760-781
- Kannankeril, P.¹ Roden, D.M.² Darbar, D.³

5
- 0034710933
- A structural basis for drug-induced long QT syndrome
- CrossRef PubMed
- Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA. 2000; 97: 12329-12333. CrossRef PubMed
- (2000) Proc Natl Acad Sci USA , vol.97 , pp. 12329-12333
- Mitcheson, J.S.¹ Chen, J.² Lin, M.³ Culberson, C.⁴ Sanguinetti, M.C.⁵

6
- 84873538403
- Antibody therapeutics targeting ion channels: Are we there yet?
- CrossRef PubMed
- Sun H, Li M. Antibody therapeutics targeting ion channels: are we there yet? Acta Pharmacol Sin. 2013; 34: 199-204. CrossRef PubMed
- (2013) Acta Pharmacol Sin , vol.34 , pp. 199-204
- Sun, H.¹ Li, M.²

7
- 84878249027
- Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency
- CrossRef PubMed
- Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med. 2013; 31: 756.e1-756.e2. CrossRef PubMed
- (2013) Am J Emerg Med , vol.31 , pp. 756e1-756e2
- Ungprasert, P.¹ Cheungpasitporn, W.² Srivali, N.³ Kittanamongkolchai, W.⁴ Bischof, E.F.⁵

8
- 23944505508
- Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey
- CrossRef PubMed
- Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil. 2005; 12: 363-368. CrossRef PubMed
- (2005) Eur J Cardiovasc Prev Rehabil , vol.12 , pp. 363-368
- Benoit, S.R.¹ Mendelsohn, A.B.² Nourjah, P.³ Staffa, J.A.⁴ Graham, D.J.⁵

9
- 77954929078
- Rituximab-induced polymorphic ventricular tachycardia
- PubMed
- Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J. 2010; 37: 218-220. PubMed
- (2010) Tex Heart Inst J. , vol.37 , pp. 218-220
- Poterucha, J.T.¹ Westberg, M.² Nerheim, P.³ Lovell, J.P.⁴

10
- 84885908052
- Polymorphic ventricular tachycardiapart I: Structural heart disease and acquired causes
- CrossRef PubMed
- Choudhuri I, Pinninti M, Marwali MR, Sra J, Akhtar M. Polymorphic ventricular tachycardiapart I: structural heart disease and acquired causes. Curr Probl Cardiol. 2013; 38: 463-496. CrossRef PubMed
- (2013) Curr Probl Cardiol , vol.38 , pp. 463-496
- Choudhuri, I.¹ Pinninti, M.² Marwali, M.R.³ Sra, J.⁴ Akhtar, M.⁵

11
- 16344377901
- Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma
- CrossRef PubMed
- Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol. 2005; 78: 317-318. CrossRef PubMed
- (2005) Am J Hematol , vol.78 , pp. 317-318
- Arai, Y.¹ Tadokoro, J.² Mitani, K.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.